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Objective: This study was aimed at evaluating the diagnostic validity of the Korean version of the Clinically Useful Depression 
Outcome Scale (CUDOS) with varying follow-up in a typical clinical setting in multiple centers. 
Methods: In total, 891 psychiatric outpatients were enrolled at the time of their intake appointment. Current diagnostic character-
istics were examined using the Structured Clinical Interview for DSM-IV (41% major depressive disorder). The CUDOS was meas-
ured and compared with three clinician rating scales and four self-report scales. 
Results: The CUDOS showed excellent results for internal consistency (Cronbach’s  0.91), test-retest reliability (patients at 
intake, r=0.81; depressed patients in ongoing treatment, r=0.89), and convergent and discriminant validity (measures of depres-
sion, r=0.80; measures of anxiety and somatization, r=0.42). The CUDOS had a high ability to discriminate between different 
levels of depression severity based on the rating of Clinical Global Impression for depression severity and the diagnostic classi-
fication of major depression, minor depression, and non-depression. The ability of the CUDOS to identify patients with major 
depression was high (area under the receiver operating characteristic curve=0.867). A score of 20 as the optimal cutoff point 
was suggested when screening for major depression using the CUDOS (sensitivity=89.9%, specificity=69.5%). The CUDOS was 
sensitive to change after antidepressant treatment: patients with greater improvement showed a greater decrease in CUDOS 
scores (p＜0.001).
Conclusion: The results of this multi-site outpatient study found that the Korean version of the CUDOS is a very useful measure-
ment for research and for clinical practice.
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INTRODUCTION
Unlike other chronic medical diseases, depression’s bi-
ological markers have not yet been identified. Thus, in an 
assessment based on the clinician’s observation and the 
patient’s report, a method of accurately measuring the se-
verity and functional activity of depression is needed. 
Moreover, the ability to represent the progress of depres-
sion using a quantifiable score is desirable.1) However, an 
objective and quantifiable measurement of depression is 
difficult to obtain due to the many limitations involved, in-
cluding human resources, time, and costs in actual clinical 
practice.2)
The Clinically Useful Depression Outcome Scale 
(CUDOS) is a useful tool for screening for depression be-
cause it fully covers the Diagnostic and Statistical Manual 
of Mental Disorders 4th edition (DSM-IV) symptoms of 
major depressive disorder (MDD) and dysthymic disorder.3) 
It also assesses the functional aspects of depression and 
sensitively evaluates remission of depression and its re-
sidual symptoms.4) The CUDOS is a brief self-administered 
questionnaire. Thus, it incurs low cost and can be applied 
simply and quickly in clinical practice. It takes two to 
three minutes to complete and the completed form can be 
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scored within 15 seconds. Good reliability and validity of 
the CUDOS have been demonstrated and it is considered 
clinically useful.3) 
The CUDOS consists of 18 items: 16 assessing the 
DSM-IV MDD symptoms, one question on psychosocial 
impairment in daily activities, and one question on quality 
of life.3) In the DSM-IV, the occurrence of depressive 
symptoms for two weeks is required to diagnose MDD, 
but the CUDOS uses a one-week duration. The shorter 
evaluation period is used so the scale can be used to meas-
ure outcome on a weekly basis. The items on MDD symp-
toms evaluate how often a subject has experienced the 
symptom in the last week using a 5-point Likert scale. 
Total scores range from 0 to 64. 
In antidepressant clinical trials, the progression of de-
pression is often evaluated using a clinician rating meas-
ure, such as the Hamilton Depression Rating Scale 
(HAMD).5) However, the HAMD takes too long to admin-
ister in routine clinical practice. Brief self-report ques-
tionnaires are considered desirable to minimize the cost 
and to evaluate the progress of depression frequently and 
quickly.1) In this sense, the CUDOS is useful for both 
clinicians and patients due to its simplicity, which im-
proves the efficiency of clinical consultations. In terms of 
simplicity, the Patient Health Questionnaire-9 (PHQ-9), 
which was developed based on DSM-IV criteria, has been 
the most useful self-administered scale.6) However, it has 
only 10 items compared to the CUDOS’ 18, so it yields 
limited information. For example, sleep pattern is not div-
ided into hypersomnia and insomnia in the PHQ-9, but is 
addressed in one item. Also, the PHQ evaluates decreased 
appetite and increased appetite in one item. Thus, im-
portant information about the patient’s symptoms may be 
missed, which may affect the treatment plan. 
The CUDOS has been translated into several lan-
guages, but it has not been translated and validated in 
Korea. It is important that translated self-rating scales for 
use in cross-cultural settings, especially in non-Western 
countries, need to be strictly evaluated before clinical 
application.7) In this study, we developed and validated the 
Korean version of the CUDOS to evaluate its potential for 
cross-cultural application for Korean subjects and to sug-
gest an optimal cut-off score among clinical outpatient 
samples. 
METHODS
Design and Setting
We conducted an observational, prospective study with 
varying follow-up in a typical clinical setting in multiple 
centers (two university hospitals and three general psychi-
atric hospitals) serving various regional communities in 
South Korea. The study protocol was approved by the in-
stitutional review board of each medical center. 
Participants
Psychiatric outpatients who satisfied the selection cri-
teria at each medical center were recruited to be partic-
ipants in this study. Participants were new patients as the 
first psychiatric examination, or had not received anti-
depressant or other psychotropic drug treatment within 
the past 4 weeks. A total of 952 patients were originally 
screened. The inclusion criteria were (i) patients aged 19 
or older, (ii) patients with cognitive function that enabled 
them to answer the questions appropriately, and (iii) pa-
tients who could read and write Korean. The exclusion cri-
teria were (i) patients with current psychotic or manic 
symptoms, (ii) patients with underlying medical disease 
that could affect study evaluation, (iii) patients who had 
participated in any clinical trial in the last six months, and 
(iv) bereavement. A total of 61 patients were excluded 
from this study: 21 had cognitive problems, 10 had medi-
cal problems, 8 had current psychotic or manic symptoms, 
and 22 failed to complete all the scales. Thus, the final 
sample included 891 subjects.
Instruments
Depressive symptoms were assessed by the Korean 
version of the CUDOS, two clinician rating scales (the 
17-item HAMD8) and the Clinical Global Impression for 
Severity [CGI-S]9)), and two self-report scales (the 
PHQ-96) and the Beck Depression Inventory [BDI]10)). In 
this study, subjects were rated using the Clinical Global 
Impression for Depression Severity (CGI-DS). In addi-
tion, anxiety symptoms were assessed by a clinician rating 
scale (the Hamilton Anxiety Rating Scale [HAM-A]11)) 
and a self-report scale (the Beck Anxiety Inventory 
[BAI]12)). Somatic symptoms were assessed with a 
self-report scale, the Patient Health Questionnaire-15 
(PHQ-15).13) All Korean versions of the administered 
measures were validated in previous studies.14-18) 
Procedures 
Three board-certified psychiatrists and three certified 
psychologists who were fluent in both English and Korean 
translated the CUDOS into Korean and back-translated it 
into English. The validated Korean version of DSM-IV 
criteria was referenced for the translation.19) Translation 
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and back-translation of the CUDOS were repeated after 
state-of-the-art procedures in cross-cultural assessment 
were implemented.20) The process was repeated until the 
clinicians felt the Korean version was equivalent to the 
English version and suitable for Korean patients. In this 
process, the investigators edited the parts that were un-
clear or could be misunderstood by Korean patients, based 
on their discussions. The final version was reviewed by a 
professional translator and scholars of Korean literature 
and was agreed upon by all the investigators.
The interviews and testing were performed by 13 
board-certified psychiatrists. All patients were also inter-
viewed by a trained diagnostic rater who applied the 
Structured Clinical Interview for DSM-IV (SCID).21) The 
subject completed the test before meeting the clinician and 
all psychiatrists were kept blinded to the subject’s re-
sponse on the measure. All subjects provided written in-
formed consent. Interrater reliability was examined in 16 
patients and was satisfactory for all scales (HAMD, 
r=0.95, p＜0.001; HAM-A, r=0.64, p＜0.001; and CGI-DS, 
r=0.90, p＜0.001). 
The test-retest reliability of the CUDOS was examined 
in 2 samples. Of the 891 subjects at the time of intake ap-
pointment, 88 returned to the study center one week later 
and completed the CUDOS a second time to exam test-re-
test reliability. A new patients at intake are highly sympto-
matic and very sensitive to the treatment over short period 
of time. Symptom changes might occur for one week 
interval. In contrast, patients in ongoing treatment are 
more clinically stable and less sensitive to treatment. 
Thus, a second sample of 28 was depressed patients in on-
going treatment. They had received treatment for at least 
4 months and were clinically stable according to clini-
cian’s interview and chart review. They completed the 
CUDOS at the time of their appointment and were asked 
to complete it again one week later. 
Of the 891 subjects, 61 subjects diagnosed as MDD at 
baseline completed the CUDOS and were evaluated using 
the HAMD a second time 8 weeks after antidepressant 
treatment to investigate sensitivity to symptom changes.
Data Analyses
Missing data were replaced with the median of the com-
pleted data in each item. The number of missing values on 
each item was less than 0.5%. The internal consistency of 
the CUDOS was evaluated using Cronbach’s  and the 
item-total correlation. Test-retest reliability and con-
vergent and discriminant validities of the CUDOS com-
pared with other measures were assessed using Pearson’s 
correlation coefficient. The ability of the CUDOS to dis-
criminate between different levels of depression severity 
was investigated based on the rating of CGI-DS and the di-
agnostic classification of major depression, minor depres-
sion, and non-depression. In turn, an analysis of variance 
and post-hoc comparison of Tukey’s honestly significant 
difference (HSD) test were used. Sensitivity and specific-
ity were evaluated by assessing the receiver operating 
characteristic (ROC) curve to obtain the optimal cutoff 
score when screening for major depression. We compared 
the ROC curves derived from the CUDOS, PHQ-9, BDI, 
and HAMD. The pairwise comparison of AUCs between 
CUDOS and other measures was investigated using meth-
od suggested by Hanley and McNeil.22) Sensitivity to 
symptom changes after antidepressant treatment were in-
vestigated with an analysis of variance and Tukey’s HSD 
test. All analyses were conducted using IBM SPSS 
Statistics ver. 20.0 for Windows (IBM Co., Armonk, NY, 
USA). All statistical tests were two-tailed.
RESULTS
Sociodemographic Characteristics and DSM-IV Diagnoses
A total of 891 subjects including 373 men (41.9%) and 
518 women (58.1%) were analyzed in this study. The 
mean subject age was 43.6±15.4 (mean ± standard devia-
tion) years (range, 20-76 years). Other demographic char-
acteristics are provided in Table 1. The current DSM-IV 
Axis I diagnoses of the 891 subjects at their initial appoint-
ment are given in Table 2. The most frequent DSM-IV di-
agnosis was MDD (n=366, 41.1%).
Subjects were classified into major depression, minor 
depression, and non-depression groups. The major de-
pression group consisted of 386 subjects who were diag-
nosed with MDD (n=366, 41.1%) or bipolar major depres-
sive episode (n=20, 2.2%). The minor depression group 
consisted of 106 subjects who were diagnosed with de-
pressive disorder not otherwise specified (n=8, 0.9%) or 
adjustment disorder with depressed mood (n=28, 3.1%) or 
dysthymic disorder (n=70, 7.9%) and were not diagnosed 
with major depression. The non-depression group con-
sisted of 399 subjects who were not diagnosed with either 
major depression or minor depression. In other words, 
these subjects had any other DSM-IV diagnoses except 
for minor depression or major depression.
Reliability
Cronbach’s  was 0.91 (p＜0.001) at baseline. The item–
total correlations ranged from 0.19 to 0.91 (mean=0.67) at 
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Table 1. Sociodemographic characteristics of subjects (n=891) 
Characteristic Number of subjects (%)
Sex
  Male 373 (41.9)
  Female 518 (58.1)
Age (yr)
  20-29 159 (17.8)
  30-39 167 (18.7)
  40-49 232 (26.0)
  50-59 193 (21.7)
  60-65  93 (10.4)     
  ＞65 47 (5.3)
Education (yr)
  0-6 328 (36.8)
  7-9 180 (20.2)
  10-12 275 (30.9)
  ＞13 108 (12.1)
Marital status
  Single 303 (34.0)
  Married 379 (42.5)
  Divorced 209 (23.5)
Table 2. Current diagnostic characteristics of the subjects (n=891) 
by the Structured Clinical Interview for the DSM-IV (SCID)
DSM-IV diagnosis
Number of 
subjects (%)
Major depressive disorder 366 (41.1)
Bipolar disorder (major depressive episode) 20 (2.2)
Depressive disorder not otherwise specified  8 (0.9)
Adjustment disorder (with depressed mood) 30 (3.4)
Adjustment disorder (without depressed mood) 13 (1.5)
Dysthymic disorder 73 (8.2)
Bipolar disorder (not major depressive episode) 59 (6.6)
Generalized anxiety disorder 65 (7.3)
Panic disorder 125 (14.0)
Social phobia 64 (7.2)
Specific phobia  8 (0.9)
Obsessive compulsive disorder 60 (6.7)
Posttraumatic stress disorder 63 (7.1)
Alcohol abuse/dependence 60 (6.7)
Somatoform disorder 129 (14.5)
Schizophrenia  4 (0.4)
Other psychiatric disorder  89 (10.0)
Subjects could be given more than one diagnosis.
baseline. The lowest item-scale correlations were for re-
verse vegetative symptoms (increased appetite [r=0.19] 
and hypersomnia [r=0.24]). The test-retest reliability co-
efficients were 0.81 (p＜0.001) in 88 patients at intake and 
0.89 (p＜0.001) in 28 depressed patients in ongoing treat-
ment
Convergent and Discriminant Validity
Table 3 shows significant positive correlations between 
the CUDOS and other measures (all, p＜0.001). The 
CUDOS was more highly correlated with measures of de-
pression (mean r=0.80) than with measures of the other 
symptom domains (mean r=0.42). 
The Ability of the CUDOS to Discriminate between 
Levels of Severity
The mean CUDOS scores of the major depression 
group, minor depression group, and non-depression group 
were 40.5±15.7, 32.3±12.7, 10.5±6.68, respectively. The 
three group analysis of variance was significant (F=62.5; 
degree of freedom [df]=2,888; p＜0.001) and the differ-
ences among the three groups were significant using 
Tukey’s HSD test. 
The ability of the CUDOS to discriminate among dif-
ferent levels of depression severity was investigated using 
an analysis of variance based on CGI-DS ratings. The total 
CUDOS score increased with increases in the CGI score: 
CGI 1 (n=17), 12.2±7.7; CGI 2 (n=138), 19.6±8.4; CGI 3 
(n=168), 27.1±10.9; CGI 4 (n=232), 32.0±13.2; CGI 5 
(n=230), 49.5±10.3; CGI 6 (n=98), 53.1±10.3; CGI 7 
(n=8), 65.0±21.3. Because the number of subjects who 
rated a 1 on the CGI (n=17) or a 7 on the CGI (n=8) were 
considered to be relatively low, the two lowest CGI rating 
levels (CGI 1, 2) and the two highest CGI rating levels 
(CGI 6, 7) were combined. The five-group analysis of var-
iance was significant (F=211.6; df=4,886; p＜0.001). 
Tukey’s test showed that the differences between each ad-
jacent CGI-DS level were significant except for the com-
parison between subjects with the CGI scores of 5 and (6 
and 7) (p=0.06). 
Receiver Operating Characteristic Analysis
The area under the ROC curve (AUC) for the CUDOS 
was 0.867 (standard error=3.5%, p＜0.001) for the diag-
nosis of major depression. The AUC values indicated that 
the CUDOS had a significantly high level of discrim-
ination (95% confidence intervals of 0.815-0.934). We se-
lected a score of 20 as the optimal cutoff point when 
screening for major depression using the CUDOS because 
this is associated with a sensitivity of 90% for identifying 
major depression in the current sample (sensitivity 89.9%, 
specificity 69.5%). A list of sensitivity and specificity 
pairs for separate scores is provided in Table 4. 
In major depression, the AUCs of the CUDOS, PHQ-9, 
BDI, and HAMD were all satisfactory (Table 5). The pair-
wise comparison of AUCs between CUDOS and other 
measures was investigated.22) There were no statistically 
significant differences between each AUC. 
Sensitivity to Change in Symptoms after Treatment
Sixty-one patients diagnosed with MDD at baseline 
32 S.W. Jeon, et al.
Table 4. The sensitivity and specificity of the CUDOS
Major depression vs. non-major depression
Cutoff score Sensitivity (%) Specificity (%)
16.0 95.4 57.7
18.0 94.1 60.5
19.0 92.3 66.3
20.0 89.9 69.5
21.0 85.2 72.4
22.0 83.3 77.4
23.0 83.3 80.7
24.0 78.8 84.5
25.0 77.8 86.8
Major depression: major depressive disorder or bipolar major 
depressive episode.
Table 5. Pairwise comparison of receiver operating characteristic 
(ROC) curves 
Major depression vs. non-major depression
AUC SE (%) 95% CI
CUDOS 0.867* 3.7 0.815-0.934
PHQ-9 0.871* 3.7 0.817-0.930
BDI 0.866* 3.5 0.798-0.889
HAMD 0.939* 3.7 0.815-0.934
AUC, area under the ROC curve; SE, standard error; CI, confidence 
interval; CUDOS, Clinically Useful Depression Outcome Scale; PHQ-9, 
Patient Health Questionnaire-9; BDI, Beck Depression Inventory; 
HAMD, Hamilton Depression Rating Scale.
*p＜0.001.
Table 3. Correlations between scores on the CUDOS and related measures 
Depression Anxiety Somatic
CUDOS HAMD CGI-DS PHQ-9 BDI HAM-A BAI PHQ-15
Depression CUDOS 1.000
HAMD 0.716 1.000
CGI-DS 0.776 0.904 1.000
PHQ-9 0.835 0.728 0.738 1.000
BDI 0.857 0.737 0.714 0.818 1.000
Anxiety HAM-A 0.248 0.325 0.774 0.312 0.541 1
BAI 0.394 0.541 0.678 0.381 0.382 0.742 1.000
Somatic PHQ-15 0.635 0.665 0.621 0.645 0.578 0.564 0.417 1.000
All correlations are significant at p＜0.001. 
CUDOS, Clinically Useful Depression Outcome Scale; HAMD, Hamilton Depression Rating Scale; CGI-DS, Clinical Global Impression for 
Depression Severity; PHQ-9, Patient Health Questionnaire-9; BDI, Beck Depression Inventory; HAM-A, Hamilton Anxiety Rating Scale; BAI, Beck 
Anxiety Inventory; PHQ-15, Patient Health Questionnaire-15. 
completed the CUDOS and were evaluated using the 
HAMD at a second visit 8 weeks after antidepressant 
treatment. There were no significant differences in the 
scores of the two scales at baseline between the 61 patients 
with MDD who attended follow-up and the 305 patients 
with MDD who did not attend follow up. The correlation 
of the HAMD to the CUDOS at follow-up were sig-
nificant (r=0.727, p＜0.001). At follow-up, the CUDOS 
and the HAMD scores were significantly decreased 
(CUDOS, 42.1±10.5 vs. 22.4±13.6, t=10.08, p＜0.001; 
the HAMD, 22.8±6.6 vs. 12.1±7.9, t=12.9, p＜0.001). 
Subjects were categorized into a remission group (n=30; 
HAMD ＜7), a responder group (n=17; ≥50% improve-
ment from baseline to follow-up but not in remission), or 
a non-responder group (n=14). At follow-up, the mean 
CUDOS scores of the remission group, responder group, 
and non-responder group were 9.7±6.7, 23.5±7.7, and 
33.2±10.6, respectively. The three-group analysis of var-
iance was significant (F=51.9; df=2,58; p＜0.001). The 
differences among the three groups were significant using 
Tukey’s HSD test.
DISCUSSION
The results of this study suggest that the Korean version 
of the CUDOS is a reliable and valid measure of the se-
verity of depressive symptoms. Consistent with the initial 
validation study of the English language version of the 
scale,3) internal consistency was high, all item-scale corre-
lations were significant, the atypical depression symp-
toms had the lowest item-scale correlations, test-retest re-
liability was high, and the CUDOS was more highly corre-
lated with other measures of depression than with meas-
ures of other symptom domains. Moreover, the ability of 
the CUDOS to discriminate among different levels of de-
pression severity was significant and the measure was 
sensitive to change after treatment. 
The AUC of 0.867 indicates that the CUDOS has ex-
cellent properties for use as a screening instrument in the 
identification of major depression. A score of 20 as the op-
timal cutoff point was suggested when screening for major 
depression. At this cutoff point, the sensitivity was 89.9% 
and the specificity was 69.5% in our sample. If the instru-
ment is intended for screening, a large number of subjects 
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should be included in the patient group first and additional 
evaluations must be conducted to make accurate diag-
noses.23) No special training is required for administering 
CUDOS, which is also used in primary care settings other 
than the psychiatric field.3) Depressed patients who need 
immediate treatment can be quickly screened using 
CUDOS before they are referred to psychiatrists. Thus, 
the sensitivity of the cutoff point must be close to 90%, 
even if its specificity is sacrificed. There are five catego-
ries in the empirically derived range of the depression se-
verity of the CUDOS: scores of 11-20 represent minimal 
depression; 21-30, mild depression; 31-45, moderate de-
pression; and 46 or higher, severe depression.3) The cutoff 
score of 20 suggested in this study belongs to the upper 
limit of the minimal depression category, which comes 
immediately before the start of the mild depression 
category. 
The CUDOS was nearly as highly correlated with 
HAMD and CGI-DS (r=0.716-0.776) as with PHQ-9 and 
BDI (r=0.835-0.857). This slightly differential pattern of 
correlations may be due to method variance of data 
collection. It is known that the method of data collection 
(self-reported vs. clinician rated) affects the degree of 
correlations.1) The AUC of HAMD (0.939) is slightly 
greater than the AUC of other self-report measures 
(CUDOS, PHQ-9, and BDI: 0.866-0.887). For the same 
reason, this differential pattern of AUC may be because 
diagnostic assessment was performed using the Structured 
Clinical Interview.
The percentage of cases of somatoform disorder was 
relatively high in our sample. Asian patients with MDD 
often have comorbid somatoform disorder.24) Many stud-
ies have reported that somatic symptoms are core features 
of depression in East Asian countries, including South 
Korea.25) The high prevalence of somatic symptoms is pri-
marily explained by the conventional concept of a disease 
as projecting emotional conflict onto physical imbalance 
and by the pattern of expression of personal relationships 
with physical language rather than exposing emotional 
suffering.26) In Confucian culture, it is not socially accept-
able to directly express emotions. East Asian patients do 
not directly complain of symptoms of depression, but in-
stead complain of accompanying symptoms of depression 
such as somatic symptoms, anxiety, attention, memory 
disturbance, or hypochondriasis.27) The relatively high 
correlation between the CUDOS and the PHQ-15 (r=0.635, 
p＜0.001) is consistent with the tendency of depressed 
East Asian patients to somaticize their problems. Future 
studies should examine whether it would be beneficial to 
include somatic symptom items to a the Diagnostic and 
Statistical Manual of Mental Disorders, fifth edition-based 
measure, so that it is more appropriate for Asian patients. 
Alternatively, using the CUDOS along with the PHQ-1513) 
or the Symptom Checklist-90 (SCL-90),28) which focuses 
on somatic symptom, may help address this problem. 
This study focuses on a practical clinical setting and 
will be more meaningful to clinicians. However, one im-
portant limitation of this study is that subjects are re-
stricted to clinical outpatients. This sample may not be 
fully representative of community-dwelling populations. 
As a result, the subjects had a high proportion of depres-
sion and the sample size of older adults was relatively 
small because many elderly subjects were excluded based 
on the exclusion criteria. Different populations do not re-
spond in the same manner to individual items on the 
CUDOS. For example, the elderly tend not to express their 
psychological distress or emotions in the same way as 
young adults.29) The generalizability to subject with dif-
ferent socio-demographic (e.g., elderly patients) or clin-
ical characteristics (e.g., medical/surgical patient setting) 
will need to be validated. Secondly, because the sample 
size rated on CGI 1 or CGI 7 were considered to be rela-
tively small, the five categories of CGI-DS instead of sev-
en were explored to identify ability to discriminate be-
tween levels of severity.
In multinational or multicenter clinical trials, the num-
ber of which is sharply increasing these days, all partic-
ipant countries or centers must provide each other with 
their measurements, which are secured by the reliability 
and validity of their evaluations of the trial groups. In de-
pression studies such as antidepressant trials, the rating 
scale is very important, particularly for objectively evalu-
ating the severity of the symptoms or the treatment effects 
of antidepressant drugs. The Clinician Rating Scale is still 
widely used for depression studies.30) However, research 
and treatments are usually conducted simultaneously in 
the busy setting of clinical practice. Accordingly, CUDOS 
is thought to be useful in depression studies because it 
saves time and cost, and its reliability and validity have 
been verified. For the same reasons, it is also expected to 
be useful for large-scale epidemiological studies.
The results of this multi-site outpatient study found that 
the Korean version of the CUDOS is reliable, valid, and 
sensitive to change in a Korean outpatient setting. The 
CUDOS appears to be a very useful measurement for both 
clinical practice and research, not only to screen for de-
pression, but to also measure the remission of depression 
and its residual symptoms. 
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